Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Generic Line > India’s Patent Laws Under Scrutiny, Ramifications Huge for Generics

Generic Line

Sept. 26, 2012 | Vol. 29 No. 19

India’s Patent Laws Under Scrutiny, Ramifications Huge for Generics

India’s patent laws are coming under more intense scrutiny, with cases that could add new difficulties for foreign multinational companies.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Briefs Deadline Looms on India’s Price Control Expansions for Generics Canadian Drugmakers Expect Higher Costs From EU Proposals EC: Scrutiny Leads to Decline in ‘Problematic’ Patent Deals

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.